Cerity Partners OCIO’s Biolase, Inc. BIOL Stock Holding History

Cerity Partners OCIO’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-14	Closed	-$14K	–	402
2020 Q4	$14K	Buy	+14	New	+$10.7K	﹤0.01%	355

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DCM Advisors New York $220M AUM 23.37% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cerity Partners OCIO's BIOL Position: Q1 2021 in Review

Cerity Partners OCIO sold out of Biolase, Inc. (BIOL) in Q1 2021, closing a stake of 14 shares — an estimated $14K sold.

Cerity Partners OCIO first reported a position in BIOL in Q4 2020 and held it in 1 quarter. The position peaked at $14K in Q4 2020. 32 funds tracked by Wall St. Rank hold BIOL as of Q1 2021.

Cerity Partners OCIO reported no remaining Biolase, Inc. position as of Q1 2021 after selling out during the quarter.
Cerity Partners OCIO sold 14 Biolase, Inc. shares in Q1 2021, an estimated $14K.
Cerity Partners OCIO first reported a position in Biolase, Inc. in Q4 2020 and held it in 1 quarter.
Cerity Partners OCIO's Biolase, Inc. position peaked at $14K in Q4 2020.
32 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2021.

Based on Cerity Partners OCIO's 13F filing for Q1 2021, filed 6 May 2021.